drugset
drugset / Trial / NCT03701490

Prolutex in Frozen Embryo Transfer Cycles At the Blastocyst Stage (PROGEX)

NCT03701490 ↗

Phase 2 Completed 213 enrolled IBSA Institut Biochimique SA
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this proof of concept clinical trial is to evaluate the impact of two different progesterone treatments for endometrial preparation (25 mg/twice-a-day, subcutaneous injection, and 200 mg/three times a day, vaginal administration) on the clinical pregnancy rate in women undergoing frozen embryo transfer (FET) at blastocyst stage.

Timeline

Start
2019-03-12
Primary completion
2022-09-28
Completion
2022-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 25 mg Subcutaneous
Subject Progesterone Other / unclassified 200 mg Subcutaneous

Indications

infertility disorder